Comparative Pharmacology
Head-to-head clinical analysis: NIASPAN versus NIASPAN TITRATION STARTER PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIASPAN versus NIASPAN TITRATION STARTER PACK.
NIASPAN vs NIASPAN TITRATION STARTER PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT-2) and reducing free fatty acid mobilization from adipose tissue via inhibition of lipolysis. It also increases HDL by reducing hepatic clearance of apoA-I.
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
Initial: 500 mg orally once daily at bedtime. Titrate: increase by 500 mg every 4 weeks to a maximum of 2000 mg once daily. Maintenance: 1000-2000 mg once daily.
None Documented
None Documented
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
Terminal elimination half-life is approximately 2-4 hours for immediate-release niacin; for extended-release (Niaspan), it is 2-6 hours. However, the pharmacodynamic effect on lipids may persist beyond plasma elimination due to prolonged receptor interaction.
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
Renal: approximately 60-76% of a dose excreted as unchanged drug and metabolites; biliary/fecal: less than 10%
Category C
Category C
Antilipemic agent
Antilipemic agent